Breast Cancer Vaccine

BN ImmunoTherapeutics reports data on breast cancer vaccine shows exceptional efficacy

Published in Oncology Business Week, December 3rd, 2006

BN ImmunoTherapeutics, Bavarian Nordic's California-based subsidiary developing vaccines against cancer, recently presented preclinical study data with the MVA-BN-HER2 vaccine showing exceptional and significant efficacy, both in terms of inducing broad immunity as well as anti-tumor activity.

In addition, immunization with MVA-BN-HER2 showed to induce an antigen-specific Th 1-type CD4 T-cell response, Her-2 specific CD8 cytotoxic T-lymphocyte response, and anti-Her-2 antibodies.

These promising results will be included in BN ImmunoTherapeutics' current filing for an investigational new drug application (IND) with the U.S. Food and Drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2006-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry